| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_55fa76c9b7175910a5bffb3e26fb5b2a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7980b3eadf6b71cf5828b1064f253cfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1a1746cad2c6a0b892f99c55b603ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a774d9d66f83abfc474739cdf5fd636a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07a6cd1392d38980827028925ffe7b33 |
| publicationDate |
2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108136010-A |
| titleOfInvention |
Combination Therapies Used to Treat Cancer |
| abstract |
The present invention relates to combination therapy comprising administering to a subject a first molecule that specifically binds human B7-H3 and a second molecule that specifically binds human PD-1 to treat cancer and/or inflammation. The present invention also relates to a pharmaceutical composition comprising a first molecule specifically binding to human B7-H3 and a second molecule specifically binding to human PD-1, said pharmaceutical composition being capable of mediating, more preferably enhancing, against Activation of the immune system in cancer cells associated with any of the various human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in a recipient subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021023108-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112300280-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113999320-A |
| priorityDate |
2015-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |